Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel Controlled, Phase I Study, Comparing the PK, PD, Safety, and Immunogenicity of Post-change CMAB807and Prolia in Healthy Chinese Subjects

NCT06361355 is registered in ClinicalTrials.gov with Taizhou Mabtech Pharmaceutical Co.,Ltd as lead sponsor.

NCT NCT06361355
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06361355 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel Controlled, Phase I Study, Comparing the PK, PD, Safety, and Immunogenicity of Post-change CMAB807and Prolia in Healthy Chinese Subjects
Lead sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase
Phase 1
Overall status
Completed
Start date
November 2, 2023
Completion date
July 5, 2024
Enrollment
128 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers